| Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates |
40 |
| Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System |
31 |
| Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives |
24 |
| Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype |
21 |
| Extracellular Vesicles and Their Potential Use in Monitoring Cancer Progression and Therapy: The Contribution of Proteomics |
20 |
| LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer |
20 |
| Current and Emerging Targets in Immunotherapy for Osteosarcoma |
19 |
| Circular RNA hsa_circ_0007142 Is Upregulated and Targets miR-103a-2-5p in Colorectal Cancer |
19 |
| Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience |
17 |
| Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors |
17 |
| Circular RNA hsa_circRNA_0007334 is Predicted to Promote MMP7 and COL1A1 Expression by Functioning as a miRNA Sponge in Pancreatic Ductal Adenocarcinoma |
17 |
| Mechanisms of Metastasis in Colorectal Cancer and Metastatic Organotropism: Hematogenous versus Peritoneal Spread |
17 |
| CD133 in Breast Cancer Cells: More than a Stem Cell Marker |
15 |
| Not Only Mutations Matter: Molecular Picture of Acute Myeloid Leukemia Emerging from Transcriptome Studies |
14 |
| Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments |
14 |
| MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer |
14 |
| Cancer Stem Cells: From Historical Roots to a New Perspective |
13 |
| Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities |
11 |
| Endothelial-to-Mesenchymal Transition (EndoMT): Roles in Tumorigenesis, Metastatic Extravasation and Therapy Resistance |
11 |
| The Cancer Microbiota: EMT and Inflammation as Shared Molecular Mechanisms Associated with Plasticity and Progression |
11 |
| UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells |
11 |
| A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements |
11 |
| Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells |
10 |
| Inadequate Nutrition Coverage in Outpatient Cancer Centers: Results of a National Survey |
10 |
| SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer |
10 |
| Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase |
10 |
| Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway |
10 |
| Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma |
10 |
| Roles of the Phosphorylation of Transcriptional Factors in Epithelial-Mesenchymal Transition |
10 |
| Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy |
10 |
| Advances in the Management of HPV-Related Oropharyngeal Cancer |
10 |
| PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications |
9 |
| Plasticity of Drug-Naive and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program |
9 |
| Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation |
9 |
| TP53 Mutations Promote Immunogenic Activity in Breast Cancer |
9 |
| iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers |
9 |
| Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma |
9 |
| The Role of Tumor-Infiltrating B Cells in Tumor Immunity |
8 |
| The Role of Nonerythroid Spectrin alpha II in Cancer |
8 |
| The Protective Effect of Dietary Phytosterols on Cancer Risk: A Systematic Meta-Analysis |
8 |
| Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor Angiogenesis |
8 |
| Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
8 |
| Long Non-Coding RNA Expression Profile Associated with Malignant Progression of Oral Submucous Fibrosis |
8 |
| DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy |
8 |
| The De Ritis and Neutrophil-to-Lymphocyte Ratios May Aid in the Risk Assessment of Patients with Metastatic Renal Cell Carcinoma |
7 |
| Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer |
7 |
| A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy |
7 |
| CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience |
7 |
| Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer |
7 |
| Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer |
7 |
